Monitor for Nasdaq listing clearance and the NeuRX BreastCheck commercial launch in H2 2026, which is the primary revenue catalyst. The $1.5M convertible note and $2.0M term loan facility provide near-term liquidity but add dilution risk. The material weakness in internal controls and restatement history warrant caution until remediation is demonstrated.
Price Chart
Executive Summary
Davion Healthcare Plc filed its 20-F annual report for FY2025, confirming it remains a pre-revenue company with no commercial sales to date. The company reported an operating loss of €0.8 million for 2025 (improved from €1.3 million in 2024) and ended the year with only €1,058 in cash, relying on CEO advances of €0.9 million and a letter of support from Malbrite Ltd for the next 12 months. The key development is the global licensing agreement with NeuRX Health Inc. for BreastCheck, valued at $220 million over 10 years, with first commercial launch expected in H2 2026, but the company also disclosed a material weakness in internal controls and the need for a restatement of prior financials.
Key Facts
- Pre-revenue company with no commercial sales; operating loss of €0.8 million in 2025 (vs €1.3 million in 2024)
- Cash and cash equivalents of only €1,058 as of December 31, 2025
- CEO Jack Kaye owed €0.9 million in advances; Malbrite Ltd provided letter of financial support for 12 months
- Global licensing agreement with NeuRX Health Inc. for BreastCheck: $120 million license fee ($20M cash + $100M in NeuRX shares over 10 years) plus minimum annual royalties of $10 million
- BreastCheck commercial launch expected in H2 2026; no other license agreements for other products
- Material weakness in internal control over financial reporting identified; restatement of 2024 and 2023 financials required
- Post-period: $1.5 million secured convertible note issued (March 2026); $2.0 million committed term loan facility (March 2026)
- Intangible assets of €65.0 million (intellectual property) not impaired; indefinite useful life maintained
- No revenue recognized in 2025; revenue recognition policy adopted for licensing arrangement
- Company awaiting Nasdaq listing clearance; registration statement effective November 28, 2025
Financial Impact
Operating loss of €0.8 million in 2025; cash position of €1,058; CEO advances of €0.9 million; licensing agreement valued at $220 million over 10 years
Risk Factors
- Pre-revenue with minimal cash; dependent on CEO support and NeuRX performance for survival
- Single-licensee concentration risk for BreastCheck; no other license agreements for remaining products
- Material weakness in internal controls may delay reporting or lead to further restatements
- Dilution risk from convertible note (139,925 shares) and advisory share issuances (225,000 shares)
- Intellectual property impairment risk if commercialization is delayed or fails
- Geopolitical and macroeconomic risks could impact consumer adoption and supply chains
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001683168-26-003389 |
| Document: davion_ex1011.htm | 0001683168-26-003389 |
| Document: davion_ex9701.htm | 0001683168-26-003389 |
| Document: davion_ex1010.htm | 0001683168-26-003389 |
| Document: davion_ex1012.htm | 0001683168-26-003389 |
| Document: davion_ex1100.htm | 0001683168-26-003389 |
| Document: davion_ex3102.htm | 0001683168-26-003389 |
| Document: davion_ex9904.htm | 0001683168-26-003389 |
| Document: davion_ex3101.htm | 0001683168-26-003389 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Press Release | $5.10 | awaiting T+20 | — | $6.00 (+17.65%) |
Oct 20, 2026 5d ago | 6-K | — | awaiting T+20 | — | — |
Sep 15, 2026 5w ago | 6-K | — | awaiting T+20 | — | — |
Apr 30, 2026 25w ago | 20-F | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers